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Abstract: Solid lipid nanoparticles (SLNs) of amikacin were designed in this study for 
  pulmonary delivery to reduce the dose or its administration intervals leading to reduction 
of its toxicities especially in long term treatment. Nanoparticles of amikacin were prepared 
from cholesterol by solvent diffusion technique and homogenization. The size, zeta potential, 
loading efficiency, and release profile of the nanoparticles were studied. The conventional 
broth macrodilution tube method was used to determine the minimum inhibitory concentra-
tion (MIC) and minimum bacteriostatic concentration (MBC) of amikacin SLNs with respect 
to Pseudomonas aeruginosa in vitro. To guarantee the stability of desired SLNs, they were 
  lyophilized using cryoprotectants. Results showed that considering the release profile of ami-
kacin from the studied nanocarrier, MIC and MBC of amikacin could be about two times less 
in SLNs of amikacin compared to the free drug. Therefore, fewer doses of amikacin in SLNs 
can clear the infection with less adverse effects and more safety. Particle size enlargement 
after   lyophilization of desired SLNs after two months storage was limited in comparison with 
non-lyophilized particles, 996 and 194 nm, respectively. Zeta potential of lyophilized particles 
was increased to +17 mV from +4 mV before lyophilization. Storage of particles in higher 
temperature caused accelerated drug release.
Keywords: amikacin, antimicrobial effects, Pseudomonas aeruginosa, solid lipid nanoparticles, 
stability
Introduction
Aminoglycosides are the mainstay in the treatment of serious Gram-negative systemic 
infections. The use of aminoglycosides can be limited because of their adverse effects, 
mainly oto- and nephrotoxicity which happens in 15%–17% of patients, hearing loss 
(8%), and vestibular toxicity (3%). Also retina toxicity was observed with gentamycin 
in vitro.1–3 Controlling aminoglycosides concentration is critical because of their narrow 
therapeutic range.3 Aminoglycosides are used for treatment of many infections, such 
as severe pulmonary infections like cystic fibrosis and skin infections, because of their 
beneficial effects.4 Many studies have been carried out so far to reduce these toxicities 
such as production of liposomal amikacin dry powder inhaler, intra-tracheal delivery 
strategy of gentamycin, and thiolated chitosan nanoparticles of amikacin.5–7 Produc-
tion of solid lipid nanoparticles (SLNs) of amikacin for pulmonary delivery was also 
reported by Varshosaz et al.8
There are some differences between liposomes and SLNs. By definition, a lipo-
some is a tiny bubble (vesicle) made out of the same material as a cell membrane 
(lipid bilayer). Liposomes can be filled with drugs and be used to deliver drugs for International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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cancer and other diseases. Membranes are usually made 
of phospholipids which are molecules that have a head 
group and a tail group. The head is hydrophilic and the tail, 
which is made of a long hydrocarbon chain, is hydrophobic. 
In nature, phospholipids are found in stable membranes 
composed of two layers (a bilayer). The heads are attracted 
to water and line up to form a surface facing the water, 
whereas the tails are repelled by water and line up to form 
a surface away from it. When membrane phospholipids are 
disrupted, they can reassemble themselves into tiny spheres, 
smaller than a normal cell, either as bilayers or   monolayers. 
The bilayer structures are liposomes. The monolayer struc-
tures are called micelles. Liposomes can be composed of 
naturally-derived phospholipids with mixed lipid chains, 
like egg phosphatidylethanolamine, or of pure surfactant 
components, like dioleoylphosphatidylethanolamine.9 SLNs 
as colloidal carrier systems combine the advantages of tradi-
tional systems, but avoid some of their major disadvantages. 
In contrast to liposomes, SLNs do not have a bilayer structure. 
They may have a matrix structure or encapsulate drugs. They 
are much more stable than liposomes. Some advantages of 
SLNs are the possibility of controlling drug release and 
drug targeting, increased drug stability, high drug payload, 
possibility of the incorporation of lipophilic and hydrophilic 
drugs, lack of biotoxicity of the carrier, no problems with 
respect to large-scale production, sterilization possibility, and 
good tolerability. However, some of the major drawbacks of 
SLNs are low drug loading, unpredictable drug release, and 
the risk of gelation due to polymorphism of the solid lipids. 
The main ingredients used to produce SLNs include solid 
lipid(s), emulsifier, and water.
There are many studies on SLNs, even for hydrophilic 
drugs and peptide delivery. The desired SLNs were made 
from cholesterol with one layer structure, smaller particle 
size, simple preparation method, and good stability that can-
didates makes then for success in scale up in future.10,11
Amikacin is 6-O-(3-amino-3-deoxy-α-1)-glucopyranosyl)-
4-O-(6-amino-6-deoxy-α-D-glucopyranosyl)-N1-[(2,S)-
4-amino- 2-hydroxybutanoyl]-2-deoxy-D-streptamine, a 
substance obtained from kanamycin A. It has positive charge. 
Amikacin sulphate having a molar ratio of amikacin to H2SO4 
of 1:2 contains the equivalent of not less than 674 µg and 
not more than 786 µg of amikacin (C22H43 N5O13) per mg, 
calculated on the dried basis. It has the following molecular 
formula C22H43N5O132H2SO4 with a molecular weight of 
781.75. Aminoglycosides like amikacin “irreversibly” bind 
to specific 30S subunit proteins and 16S rRNA. Amikacin 
inhibits protein synthesis by binding to the 30S ribosomal 
subunit to prevent the formation of an   initiation complex 
with mRNA. Specifically amikacin binds to four nucleotides 
of 16S rRNA and a single amino acid of protein S12. This 
interferes with the decoding site in the vicinity of nucleotide 
1400 in 16S rRNA of 30S subunit. This region interacts 
with the wobble base in the anticodon of tRNA. This leads 
to interference with the initiation complex and misreading 
of mRNA so incorrect amino acids are inserted into the 
polypeptide leading to nonfunctional or toxic peptides and 
the breakup of polysomes into nonfunctional monosomes. 
Amikacin is a semisynthetic broad spectrum aminoglyco-
side antibiotic derived from kanamycin A by acetylation. 
It is commonly administered parenterally for the treatment 
of Gram-negative infections resistant to gentamycin, kana-
mycin, and tobramycin because the amikacin molecule has 
fewer points susceptible to enzymatic attack than the other 
aminoglycosides.4,9,12 Commonly used aminoglycosides 
include tobramycin, gentamycin, and amikacin.2 For treat-
ment of cystic fibrosis, combination therapy with an amino-
glycoside, a broad spectrum betalactam antibiotic is given 
intravenously for 14–21 days.4
The minimum inhibitory concentration (MIC) of amikacin 
is 8 µg/mL for Pseudomonas aeruginosa.1 In previous studies 
it has been reported that liposomal encapsulated tobramycin 
showed considerable antimicrobial effect at concentrations 
below the MIC of the free antibiotic in vitro.2,13 Therefore, 
reducing the effective concentration of aminoglycosides can 
be a challenge to reduce their adverse effects.
In the present study the minimum effect of SLNs of 
amikacin was investigated and compared with MIC of the 
free drug. The SLNs of amikacin were prepared for minimum 
size and maximum drug-loading efficiency using cholesterol 
as the dipodic ingredient. At first, the release profile of the 
drug from SLNs was studied, then a screening was performed 
to show the MIC of SLNs of amikacin.
To investigate the stability condition of desired nanopar-
ticles, three different conditions were selected and desired 
SLNs were stored for two months and their physicochemi-
cal properties investigated for both particle dispersion and 
freeze-dried particles. The antimicrobial efficiency of both 
dispersion and dried SLNs was the same in first step of 
production.
Material and methods
Materials
Cholesterol, Tween 80, ethanol, acetone, and Muller-Hinton 
agar were all from Merck Chemical Company (Darmstadt, 
Germany). P. aerogynosa (American Type Culture Collection International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
37
Amikacin loaded solid lipid nanoparticles
[ATCC] 9027) was obtained from the microbiology laboratory 
in   Tehran University of Medical Sciences (Tehran, Iran).
Preparation of sLNs of amikacin
The SLNs of amikacin were prepared as our previously 
reported method8 to achieve optimized particles from a 
particle size and drug-loading efficiency point of view. 
Briefly, 160 mg of amikacin powder was dissolved in 
deionized water containing 1% w/w Tween 80 and homog-
enized at 11,000 rpm (T 18 basic Ultra-Turrax; IKA Werke 
GmbH, Staufen, Germany). Then 314 mg of cholesterol 
(0.81 mmol) as lipid phase was dissolved in 24 mL of 
the mixture of ethanol/acetone with the ratio of 3:1 (v/v) 
(equal to 18 mL ethanol and 6 mL acetone) by heating to 
70°C and stirring. Then hot oily phase was added to aque-
ous phase in 25°C under homogenization at 11,000 rpm 
for 6 min. The prepared emulsion was sonicated in bath 
sonicator (Tecno-Gaz Ultrasonic system; Tecna S.p.A, 
Bologna, Italy) and cooled to room temperature to achieve 
nanoparticles. SLNs were produced in optimum level and 
type of surfactant, optimum rate and time of homogeniza-
tion, and ratio of lipid:drug to achieve smallest particles 
with maximum drug-loading efficiency using central 
composite design.8
Particle size and zeta potential of produced SLNs were 
measured using photon correlation spectroscopy (Zetasizer 
Nano ZS 3000; Malvern Instruments, Worcestershire, UK).
Drug-loading efficiency
Loading efficiency of amikacin in SLNs was calculated by Eq. 
1.8,14 In this method the concentration of entrapped amikacin 
was calculated from the difference between the total amount 
of drug used for preparing SLNs and the free remaining drug 
in the medium. To do this, after preparing SLNs the emul-
sion containing SLNs was centrifuged (Sigma Laboratories, 
Osterode, Germany) at 35,000 rpm for 45 min at −4°C and 
concentration of amikacin in supernatant was analyzed by 
high-performance liquid   chromatography (HPLC).8
Drug-loading 
 
efficiency(LE%)
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− Drug Drug
D
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×100
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release study
Release study was performed using dialysis method. Five mL 
of the optimized formulation before freeze-drying was placed 
in DO405 dialysis tubing 23 × 15 mm (cut-off: 10–12 KD; 
Sigma Laboratories, Osterode, Germany) immersed in 50 mL 
of phosphate buffer solution (pH 7.4). One mL sample 
was withdrawn at predetermined time intervals and drug 
  concentration was analyzed using pre-column derivatization 
by HPLC method.8 Drug release profile was studied in dif-
ferent temperature conditions for SLNs of amikacin solution 
in first dispersion and redispersed freeze-dried nanoparticles 
after storage at 4°C, 25°C, and 40°C for 60 days.
Freeze drying
Lyophilization was used to prolong stability of amikacin 
loaded SLNs. Lyophilization of particles was done using 
cryoprotectants like sucrose, dextrose, and mannitol to 
limit the risk of aggregation of particles. The process was 
optimized using D-optimal experimental design reported 
previously.15
stability study
The initial particle size and zeta potential of the amikacin 
loaded nanoparticles dispersion were measured immediately 
after preparation and after freeze drying, and redispersion of 
particles in deionized water by bath sonication for 5 s using 
Zetasizer Nano ZS3000 (Malvern, UK). This batch was 
divided into three sample sets and each sample set was stored 
at 4°C, 25°C, and 40°C–4°C being refrigerator conditions, 
25°C for room temperature, and 40°C as the indicative hot 
climate areas that the drug may be stored during distribution 
from the manufacturer to the end user.
All samples were stored in plain glass vials (USP type 1). 
Samples were withdrawn after 1, 3, 7, 15, 30, 45, and 60 days 
and subjected to particle size and zeta potential measure-
ments. Polydispersity index (PDI) and drug released in 
deionized water containing 1% w/w Tween 80 were studied. 
However, measurement of released fraction of drug was 
checked just after 60 days as the samples were dry and had 
no risk of drug release.16
Morphology study
Morphology of the nanoparticles was characterized by scan-
ning electron microscopy (SEM). The nanoparticles were 
mounted on aluminum stubs, sputter-coated with a thin 
layer of Au/Pd, and examined using an SEM (Philips XL30; 
Philips, Almelo, The Netherlands).
Antimicrobial activity of sLNs
To determine if there is any relationship between the activity 
of SLNs of amikacin and drug release profile from colloidal 
vehicle, and also to compare between the activity of nano-
particles of amikacin (directly after preparing particles in 
original medium and after lyophilization of SLNs and then International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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dispersed in water) with that of free drug, the “well diffusion 
test” was carried out using P. aeruginosa (ATCC 9027) as 
the Gram-negative pathogenic strain.
The bacterial suspensions with a cell density equivalent 
to 0.5 McFarland (1.5 × 108 CFU/mL) were transferred 
individually onto the surface of Muller–Hinton agar plates 
using sterile cotton swabs. Wells with 8 mm diameters 
were prepared by punching a sterile cork borer onto agar 
plates and removing the agar to form a well. Aliquots of 
100 µl of each of two control solutions, free-drug and 
blank-SLNs, were delivered into the wells. A third well 
was full with SLNs of amikacin as the test sample. After 
incubation time for about 24–48 h, at 35°C–37°C, the 
zones of inhibition around the wells were measured in 
mm using a caliper.
Determination of MIc and minimum 
bacteriostatic concentration of sLNs 
against the pathogen
The conventional broth macrodilution tube method was used 
to determine MIC and minimum bacteriostatic concentration 
(MBC) of SLNs of amikacin with respect to P. aeruginosa 
as Gram-negative pathogenic bacteria in vitro.17,18 A stock 
solution of free amikacin was prepared in sterile water 
(64 µg/mL) that was further diluted in Muller–Hinton broth 
to reach a concentration range of 0.125 to 32 µg/mL. SLNs 
were also dispersed in Muller–Hinton broth to reach an 
equal concentration of free amikacin as 0.125 to 32 µg/mL 
according to the percent of drug loading.
Final concentration of bacteria in individual tubes was 
adjusted to about 5 × 106 CFU/mL. Control tubes contained 
only culture media without any antimicrobial agent, culture 
media with SLNs of amikacin due to probable contamination. 
Other test tubes included culture media with pathogenic strain 
(in 5 × 106 CFU/mL), culture media with amikacin SLNs and 
pathogenic strain (in 5 × 106 CFU/mL), and culture media 
with P. aeruginosa (in 5 × 106 CFU/mL) with free amikacin 
in MIC (8 µg/mL), as was previously measured.1,2
After 24 and 48 h incubation at 35°C–37°C, the test 
tubes were examined for possible bacterial turbidity and 
MBC and MIC of each test compound was determined 
respectively as lowest concentration that could stop and 
inhibit visible bacterial growth for 24 h and 72 h.12,13 Figure 1 
demonstrates the method of the MIC and MBC testing. A 
study was done on both freeze-dried and nonfreeze-dried 
SLNs of amikacin.
Results and discussion
Particle size
The size and zeta potential of the particles before freeze 
drying were 150 ± 4 nm and + 4 mV, respectively, 
and after freeze drying these increased to 190 ± 7 nm 
and + 16 mV. The percentage of drug-loading efficiency 
was 87% ± 4%.
MIC
MBC
Growth
No 
growth
Inoculation from MIC
cultures into 
antimicrobial-free media
0.25 0.5 1.0 2.0 4.0 8.0 16.0
Figure 1 Design of serial dilution susceptibility testing method.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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Drug release profiles  
and antimicrobial activity
The release profile of amikacin from SLNs dispersion is 
shown in Figure 2a and 2b. Figure 2a shows the percentage 
of the drug released from the cholesterol carrier which was 
sustained for 70, 144, and 240 h at 40°C, 25°C, and 4°C, 
respectively. The differences between different tempera-
tures before lyophilization are quite statistically significant 
(Figure 2a), but after lyophilization the differences are only 
significant between 4°C and 40°C, and release was acceler-
ated by increasing the storage temperature from 4°C to 40°C 
(Figure 2b). Desired freeze-dried SLNs were stored at 4°C, 
25°C, and 40°C, and drug release studies were done on each 
sample. Results show that after freeze drying only an early 
time burst release could be observed. By increasing the 
  storage temperature, drug release was also accelerated.
The antimicrobial activity of SLNs of amikacin after 
preparation in first dispersion is shown in Figure 3a and anti-
microbial activity of lyophilized particles after redispersion 
is shown in Figure 3b. It can be seen that SLNs of amikacin 
possessed antimicrobial activity against P. aeruginosa. 
Although the antimicrobial activity of drug-loaded SLNs was 
less than that of free drug (Table 1), it should be considered 
as it is shown in Figure 2a, that at 25°C after 24 h only about 
12% of the loaded drug could be released from the carrier in 
vitro and this reached about 25% and 33% after 48 and 72 h, 
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respectively. The percentage of drug release reaches to more 
than 95% of the loaded drug after about 144 h. While in com-
parable time in which the antimicrobial effect was studied, 
in 48 h only 25% of amikacin was released from the SLNs 
dispersion. In this   condition, the MIC and MBC of SLNs of 
amikacin was 16 and 8 µg/mL versus 8 and 4 µg/mL for free 
amikacin (Table 1) while the total concentration of released 
drug from SLNs of amikacin at this time is one fourth of 
the total concentration of free drug. Therefore, it could be 
estimated that the MIC and MBC of amikacin is half of the 
free drug in vivo after release of the entire loaded drug from 
the carrier. This more potent effect of SLNs of amikacin 
could be due to easier diffusion of lipid nanoparticles into 
the cellular membrane of P. aeruginosa cells as the lipid 
character of the cholesterol used in their production is similar 
to the cell wall of the bacteria. It may be concluded that this 
carrier could help with better transfer of aminoglycosides 
into the site of their action and possibly reduce the required 
dose and consequently the undesired side effects. Also small 
particle size of the desired SLNs may enhance diffusion of 
drug into the bacterial cell.
Previously, Beaulac et al, reported that the liposome for-
mulation composed of dipalmitoylphosphatidylcholine and 
dimyristoylphosphatidylglycerol encapsulating tobramycin 
showed a considerable antibiotic effect at concentration 
below the MIC of the free antibiotic in vitro.13 They argued 
that the enhanced antimicrobial effect may be due to a fusion 
mechanism of liposome formulation with the bacteria cell 
wall. Other studies were carried out concerning intracellular 
bacteria; they reported the possibility of further improving 
liposomal drug efficacy toward infected cells.19,20 It seems 
that SLNs and liposomal structures are both composed of 
lipids and may be comparable.
Freeze drying
The optimum condition for lyophilization was evaluated 
for the type and percentage of cryoprotectant and freezing 
temperature, the best results achieved with 12% w/w of 
sucrose as cryoprotectant at −80°C. As the results are shown 
elsewhere,16 in this condition the increase in particle size 
was minimum, the release profile changes were minimum, 
and SEM pictures showed spherical particles similar prior 
to freeze drying. Also increasing the charge of particles 
caused more stability after redispersion.16
Morphology study
SEM pictures of amikacin loaded SLNs are shown in 
Figure 4a–4d. Figure 4a, relates to the SLNs of amikacin 
which were stored at 4°C for 60 days, aggregation of 
particles was not seen. Figure 4b and 4c shows SEM pic-
tures of amikacin loaded nanoparticles stored at 25°C and 
40°C, respectively. Aggregation of particles and particle 
size enlargement were seen in these temperatures due to 
melting of cholesterol. Figure 4d shows SEM picture of 
lyophilized redispersed particles, this figure confirms that 
freeze drying doesn’t have any significant impact on the 
shape and size of SLNs.
stability study
Table 2 shows the stability of freeze-dried SLNs stored in 
different temperatures. Comparison of particle sizes before 
and after lyophilization showed that after freeze drying an 
A
B
Blank SLN
SLN loaded
with drug
Free drug
Free drug
Blank SLNs SLNs after
freeze drying
Figure 3 Photographs of the zone of inhibition produced by free amikacin and its 
sLNs in A) primary dispersion of sLNs and B) after freeze drying and re-dispersion 
of sLNs.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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initial particle, size enlargement could be seen (190 nm after 
lyophilization versus 150 nm before), but storage of freeze-
dried particles, at higher temperatures did not cause any 
significant particle size increase. However, when amikacin 
loaded SLNs were stored in dispersion form (without freeze 
drying process), increasing storage temperature caused a 
rapid particle size growth (Table 2 and Figure 4a–4c). The 
zeta potential of SLNs after lyophilization was higher than 
nonlyophilized particles, almost all PDIs were less than 
0.5 after freeze drying. Antimicrobial effects of amikacin 
did not change by lyophilization of particles and release 
profile of drug from freeze-dried particles was no differ-
ent when particles were stored at different temperatures. 
In all conditions just a burst effect (20%) was observed, 
but release profile of the prepared dispersion of SLNs of 
amikacin that was stored at different temperatures showed 
differences (Figure 2b). Stability studies confirmed that 
lyophilization could be a suitable method to increase 
stability of particles over time. As Table 2 shows, after 
freeze drying zeta potential of particles was increased and 
this could be the result of decreasing the risk of particles 
aggregation and enlargement after redispersion. Also, after 
freeze drying particle size did not increase as much as 
increasing MIC and MBC in comparison with nonfreeze-
dried SLNs (Figure 3a and 3b). Acceleration of drug release 
via cholesterol at higher storage temperatures could be 
because of melting cholesterol at higher temperatures and 
disturbing the crystalline structure of lipid carrier by heat-
ing. After freeze drying the SLNs and storage of nanopar-
ticles at different temperatures, redispersed particles did 
Table 1 MBc and MIc of free amikacin and sLNs of amikacin before and after freeze drying with respect to Pseudomonas aeruginosa
Type of antibacterial activity Free amikacin (μg/mL) Amikacin-SLNs (μg/mL)
After freeze drying Before freeze drying
MBc 4 8 8
MIc 8 16 16
Abbreviations: MBc, minimum bacteriostatic concentration; MIc, minimum inhibitory concentrations; sLN, solid lipid nanoparticles.
A
C D
B
Figure 4 seM photographs of sLNs of amikacin stored 60 days at A) 4°c, B) 25°c, C) 40°c, and D) lyophilized sLNs stored at 40°c.International Journal of Nanomedicine 2011:6 submit your manuscript | www.dovepress.com
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not show any difference when stored at different conditions   
(4°C, 25°C, and 40°C), and in all of them just some 
burst release was observed. Therefore, by lyophilization 
of desired SLNs of amikacin, stability of particles was 
increased without any significant changes in antimicrobial 
effects. Figure 4a–4d confirms that freeze drying could be 
a suitable technique to reduce risk of particle size enlarge-
ment and particles aggregation.
Conclusion
The aim of this study was to evaluate the efficacy of the ami-
kacin SLNs after preparation in the form of primary dispersion 
and redispersed freeze-dried particles in comparison with free 
drug. The loaded drug showed less MIC and MBC than free 
amikacin for both primary SLN dispersion and redispersed 
lyophilized particles. Some probable reasons were the lipo-
philic nature of SLNs which enhanced cellular entrance of 
drug into bacterial membrane and the small size of particles. 
  Consequently it could be concluded that aminoglycosides might 
be administered in lower doses or longer intervals by delivering 
as solid lipid nanoparticles to reduce their side effects.
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